# A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

> **NCT00637247** · PHASE2 · COMPLETED · sponsor: **AmpliMed Corporation** · enrollment: 142 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** imexon in combination with gemcitabine
- **DRUG:** imexon placebo + gemcitabine

## Key facts

- **NCT ID:** NCT00637247
- **Lead sponsor:** AmpliMed Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637247, "A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00637247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*